See more : Cool Company Ltd (COOL.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Recordati Industria Chimica e Farmaceutica S.p.A., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- China Shengmu Organic Milk Limited (1432.HK) Income Statement Analysis – Financial Results
- Hansa Biopharma AB (publ) (HNSA.ST) Income Statement Analysis – Financial Results
- Leader Harmonious Drive Systems Co., Ltd. (688017.SS) Income Statement Analysis – Financial Results
- Just Dial Limited (JUSTDIAL.BO) Income Statement Analysis – Financial Results
- Prochem S.A. (PRM.WA) Income Statement Analysis – Financial Results
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
About Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.08B | 1.85B | 1.58B | 1.45B | 1.48B | 1.35B | 1.29B | 1.15B | 1.05B | 987.36M | 941.63M | 828.32M | 762.04M | 728.13M | 747.52M | 689.63M | 628.44M | 576.19M | 576.08M | 488.31M | 487.54M |
| Cost of Revenue | 600.76M | 566.74M | 427.73M | 406.83M | 436.90M | 395.57M | 382.75M | 360.96M | 335.21M | 327.05M | 327.33M | 293.56M | 259.98M | 240.07M | 235.62M | 222.20M | 206.35M | 192.01M | 200.62M | 179.27M | 199.75M |
| Gross Profit | 1.48B | 1.29B | 1.15B | 1.04B | 1.04B | 956.67M | 905.37M | 792.98M | 712.47M | 660.30M | 614.30M | 534.76M | 502.06M | 488.07M | 511.90M | 467.44M | 422.09M | 384.18M | 375.46M | 309.03M | 287.79M |
| Gross Profit Ratio | 71.15% | 69.42% | 72.93% | 71.92% | 70.52% | 70.75% | 70.29% | 68.72% | 68.00% | 66.88% | 65.24% | 64.56% | 65.88% | 67.03% | 68.48% | 67.78% | 67.16% | 66.68% | 65.17% | 63.29% | 59.03% |
| Research & Development | 255.75M | 220.10M | 166.14M | 146.24M | 129.68M | 109.69M | 100.26M | 83.71M | 76.74M | 85.27M | 74.73M | 63.41M | 55.96M | 68.84M | 69.45M | 58.86M | 49.12M | 45.40M | 44.96M | 37.31M | 32.77M |
| General & Administrative | 128.25M | 109.49M | 84.50M | 72.79M | 72.78M | 67.72M | 65.58M | 64.78M | 58.98M | 57.17M | 54.09M | 45.49M | 45.39M | 44.03M | 43.72M | 39.37M | 33.93M | 27.17M | 25.30M | 21.84M | 21.13M |
| Selling & Marketing | 472.86M | 462.67M | 396.39M | 349.07M | 372.80M | 333.50M | 330.79M | 304.44M | 293.20M | 282.95M | 275.19M | 250.57M | 232.16M | 216.48M | 223.72M | 214.25M | 202.04M | 191.13M | 192.34M | 156.00M | 148.03M |
| SG&A | 601.11M | 572.16M | 480.89M | 421.86M | 445.59M | 401.22M | 396.38M | 369.22M | 352.18M | 340.12M | 329.28M | 296.05M | 277.55M | 260.50M | 267.44M | 253.62M | 235.97M | 218.29M | 217.64M | 177.84M | 169.17M |
| Other Expenses | 66.71M | 497.00K | -652.00K | 1.71M | -2.54M | -841.00K | -1.46M | 181.00K | -1.32M | 26.00K | -1.06M | -1.35M | -2.41M | 0.00 | -3.75M | 0.00 | 0.00 | -2.16M | 0.00 | 1.11M | -36.15M |
| Operating Expenses | 923.56M | 792.26M | 647.03M | 568.09M | 575.27M | 510.91M | 496.63M | 452.93M | 428.92M | 425.39M | 404.01M | 352.21M | 338.58M | 333.29M | 349.70M | 322.71M | 290.59M | 263.83M | 264.33M | 218.61M | 206.76M |
| Cost & Expenses | 1.52B | 1.36B | 1.07B | 974.92M | 1.01B | 906.48M | 879.39M | 813.89M | 764.13M | 752.44M | 731.34M | 645.77M | 598.56M | 573.35M | 585.32M | 544.90M | 496.94M | 455.85M | 464.95M | 397.88M | 406.51M |
| Interest Income | -402.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -520.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 74.46M | 34.45M | 20.90M | 17.48M | 20.10M | 22.28M | 13.53M | 11.57M | 12.24M | 16.63M | 10.23M | 6.78M | 5.07M | 3.79M | 5.80M | 6.58M | 4.07M | 2.16M | 4.13M | 4.81M | 6.45M |
| Depreciation & Amortization | 142.67M | 125.76M | 97.59M | 93.67M | 78.25M | 56.86M | 48.15M | 37.93M | 38.48M | 42.79M | 34.71M | 24.75M | 24.27M | 26.95M | 34.81M | 29.44M | 25.97M | 23.31M | 22.06M | 21.14M | 26.74M |
| EBITDA | 708.16M | 559.35M | 596.31M | 566.83M | 544.36M | 501.50M | 456.66M | 377.71M | 321.76M | 277.30M | 244.49M | 191.87M | 187.74M | 181.73M | 193.27M | 174.17M | 157.47M | 143.65M | 133.19M | 115.19M | 71.63M |
| EBITDA Ratio | 34.01% | 33.41% | 37.74% | 39.58% | 36.74% | 36.96% | 35.06% | 32.90% | 30.53% | 28.17% | 25.44% | 24.88% | 24.64% | 24.96% | 25.85% | 25.26% | 25.06% | 24.93% | 23.12% | 23.07% | 14.69% |
| Operating Income | 558.01M | 437.33M | 490.19M | 469.02M | 465.27M | 442.22M | 406.49M | 327.42M | 278.52M | 231.03M | 195.42M | 166.96M | 163.48M | 154.78M | 162.20M | 144.73M | 131.50M | 120.34M | 111.13M | 90.43M | 81.03M |
| Operating Income Ratio | 26.80% | 23.60% | 31.02% | 32.37% | 31.40% | 32.70% | 31.56% | 28.37% | 26.58% | 23.40% | 20.75% | 20.16% | 21.45% | 21.26% | 21.70% | 20.99% | 20.92% | 20.89% | 19.29% | 18.52% | 16.62% |
| Total Other Income/Expenses | -66.97M | -35.89M | -26.84M | -13.36M | -21.12M | -24.28M | -17.38M | -10.14M | -13.08M | -16.26M | -14.63M | -14.44M | -3.47M | -3.79M | -9.55M | -6.58M | -4.07M | -2.16M | -4.13M | -15.00K | -42.60M |
| Income Before Tax | 491.04M | 401.44M | 463.35M | 455.66M | 444.14M | 417.94M | 389.12M | 317.28M | 265.44M | 214.78M | 180.80M | 160.34M | 160.01M | 151.00M | 152.65M | 138.15M | 127.43M | 118.18M | 107.00M | 86.72M | 38.44M |
| Income Before Tax Ratio | 23.58% | 21.66% | 29.32% | 31.45% | 29.97% | 30.91% | 30.21% | 27.50% | 25.34% | 21.75% | 19.20% | 19.36% | 21.00% | 20.74% | 20.42% | 20.03% | 20.28% | 20.51% | 18.57% | 17.76% | 7.88% |
| Income Tax Expense | 101.82M | 89.10M | 77.38M | 100.63M | 75.28M | 105.51M | 100.32M | 79.85M | 66.63M | 53.58M | 47.10M | 41.84M | 43.57M | 42.42M | 42.09M | 37.72M | 42.56M | 44.15M | 38.44M | 32.76M | 14.69M |
| Net Income | 389.21M | 312.34M | 385.97M | 354.98M | 368.83M | 312.38M | 288.76M | 237.41M | 198.79M | 161.19M | 133.68M | 118.48M | 116.43M | 108.57M | 110.56M | 100.42M | 84.87M | 74.03M | 64.54M | 53.13M | 23.75M |
| Net Income Ratio | 18.69% | 16.85% | 24.43% | 24.50% | 24.89% | 23.10% | 22.42% | 20.57% | 18.97% | 16.33% | 14.20% | 14.30% | 15.28% | 14.91% | 14.79% | 14.56% | 13.50% | 12.85% | 11.20% | 10.88% | 4.87% |
| EPS | 1.86 | 1.52 | 1.87 | 1.73 | 1.80 | 1.53 | 1.40 | 1.15 | 0.97 | 0.79 | 0.66 | 0.59 | 0.58 | 0.55 | 0.56 | 0.51 | 0.43 | 0.37 | 0.33 | 0.27 | 0.12 |
| EPS Diluted | 1.86 | 1.49 | 1.85 | 1.70 | 1.76 | 1.49 | 1.38 | 1.14 | 0.95 | 0.77 | 0.63 | 0.56 | 0.56 | 0.52 | 0.54 | 0.50 | 0.42 | 0.36 | 0.31 | 0.26 | 0.12 |
| Weighted Avg Shares Out | 209.14M | 205.58M | 206.01M | 205.76M | 204.96M | 204.38M | 207.03M | 206.12M | 205.27M | 203.57M | 201.59M | 199.72M | 199.37M | 198.17M | 197.22M | 196.67M | 198.56M | 200.05M | 198.05M | 196.49M | 195.60M |
| Weighted Avg Shares Out (Dil) | 209.14M | 209.06M | 209.08M | 209.06M | 209.08M | 209.09M | 209.10M | 209.17M | 209.03M | 209.06M | 211.85M | 211.58M | 209.41M | 198.17M | 204.36M | 196.67M | 203.51M | 206.21M | 205.55M | 204.35M | 200.40M |
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q1 2021 Results - Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q4 2020 Results - Earnings Call Transcript
5 High-Quality Stocks in the Mediterranean
Source: https://incomestatements.info
Category: Stock Reports